FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129202918> ?p ?o ?g. }

• W2129202918 endingPage "2436" @default.
• W2129202918 startingPage "2426" @default.
• W2129202918 abstract "Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian target of rapamycin (mTOR) complexes. The dysregulation of this pathway has been implicated in tumor initiation, cell growth and survival, invasion and angiogenesis, thus, PI3K and mTOR are promising therapeutic targets for cancer. We discovered GDC-0980, a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with excellent pharmacokinetic and pharmaceutical properties. GDC-0980 potently inhibits signal transduction downstream of both PI3K and mTOR, as measured by pharmacodynamic (PD) biomarkers, thereby acting upon two key pathway nodes to produce the strongest attainable inhibition of signaling in the pathway. Correspondingly, GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers. Treatment of cancer cell lines with GDC-0980 resulted in G1 cell-cycle arrest, and in contrast to mTOR inhibitors, GDC-0980 induced apoptosis in certain cancer cell lines, including those with direct pathway activation via PI3K and PTEN. Low doses of GDC-0980 potently inhibited tumor growth in xenograft models including those with activated PI3K, loss of LKB1 or PTEN, and elicited an exposure-related decrease in PD biomarkers. These preclinical data show that GDC-0980 is a potent and effective dual PI3K/mTOR inhibitor with promise for the clinic." @default.
• W2129202918 created "2016-06-24" @default.
• W2129202918 creator A5011579222 @default.
• W2129202918 creator A5013663538 @default.
• W2129202918 creator A5017092612 @default.
• W2129202918 creator A5023165886 @default.
• W2129202918 creator A5030889513 @default.
• W2129202918 creator A5036398076 @default.
• W2129202918 creator A5037266029 @default.
• W2129202918 creator A5038260469 @default.
• W2129202918 creator A5040867393 @default.
• W2129202918 creator A5044413582 @default.
• W2129202918 creator A5051871004 @default.
• W2129202918 creator A5055370060 @default.
• W2129202918 creator A5061081453 @default.
• W2129202918 creator A5064304128 @default.
• W2129202918 creator A5067239526 @default.
• W2129202918 creator A5068764000 @default.
• W2129202918 creator A5068951320 @default.
• W2129202918 creator A5075660811 @default.
• W2129202918 creator A5076348323 @default.
• W2129202918 creator A5082418715 @default.
• W2129202918 creator A5084717735 @default.
• W2129202918 creator A5089729434 @default.
• W2129202918 creator A5090171528 @default.
• W2129202918 date "2011-12-01" @default.
• W2129202918 modified "2023-10-17" @default.
• W2129202918 title "GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway" @default.
• W2129202918 cites W1974022382 @default.
• W2129202918 cites W1981711832 @default.
• W2129202918 cites W1988338260 @default.
• W2129202918 cites W1999070116 @default.
• W2129202918 cites W2001873321 @default.
• W2129202918 cites W2001932120 @default.
• W2129202918 cites W2014031706 @default.
• W2129202918 cites W2014687655 @default.
• W2129202918 cites W2029754521 @default.
• W2129202918 cites W2035029345 @default.
• W2129202918 cites W2043386029 @default.
• W2129202918 cites W2060346337 @default.
• W2129202918 cites W2080677621 @default.
• W2129202918 cites W2087861588 @default.
• W2129202918 cites W2093178422 @default.
• W2129202918 cites W2099019742 @default.
• W2129202918 cites W2110024172 @default.
• W2129202918 cites W2115484306 @default.
• W2129202918 cites W2127429864 @default.
• W2129202918 cites W2143695256 @default.
• W2129202918 cites W2146414563 @default.
• W2129202918 cites W2148823465 @default.
• W2129202918 cites W2153672941 @default.
• W2129202918 cites W2154836325 @default.
• W2129202918 cites W2158305336 @default.
• W2129202918 cites W2162401315 @default.
• W2129202918 cites W2334084990 @default.
• W2129202918 doi "https://doi.org/10.1158/1535-7163.mct-11-0446" @default.
• W2129202918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21998291" @default.
• W2129202918 hasPublicationYear "2011" @default.
• W2129202918 type Work @default.
• W2129202918 sameAs 2129202918 @default.
• W2129202918 citedByCount "203" @default.
• W2129202918 countsByYear W21292029182012 @default.
• W2129202918 countsByYear W21292029182013 @default.
• W2129202918 countsByYear W21292029182014 @default.
• W2129202918 countsByYear W21292029182015 @default.
• W2129202918 countsByYear W21292029182016 @default.
• W2129202918 countsByYear W21292029182017 @default.
• W2129202918 countsByYear W21292029182018 @default.
• W2129202918 countsByYear W21292029182019 @default.
• W2129202918 countsByYear W21292029182020 @default.
• W2129202918 countsByYear W21292029182021 @default.
• W2129202918 countsByYear W21292029182022 @default.
• W2129202918 countsByYear W21292029182023 @default.
• W2129202918 crossrefType "journal-article" @default.
• W2129202918 hasAuthorship W2129202918A5011579222 @default.
• W2129202918 hasAuthorship W2129202918A5013663538 @default.
• W2129202918 hasAuthorship W2129202918A5017092612 @default.
• W2129202918 hasAuthorship W2129202918A5023165886 @default.
• W2129202918 hasAuthorship W2129202918A5030889513 @default.
• W2129202918 hasAuthorship W2129202918A5036398076 @default.
• W2129202918 hasAuthorship W2129202918A5037266029 @default.
• W2129202918 hasAuthorship W2129202918A5038260469 @default.
• W2129202918 hasAuthorship W2129202918A5040867393 @default.
• W2129202918 hasAuthorship W2129202918A5044413582 @default.
• W2129202918 hasAuthorship W2129202918A5051871004 @default.
• W2129202918 hasAuthorship W2129202918A5055370060 @default.
• W2129202918 hasAuthorship W2129202918A5061081453 @default.
• W2129202918 hasAuthorship W2129202918A5064304128 @default.
• W2129202918 hasAuthorship W2129202918A5067239526 @default.
• W2129202918 hasAuthorship W2129202918A5068764000 @default.
• W2129202918 hasAuthorship W2129202918A5068951320 @default.
• W2129202918 hasAuthorship W2129202918A5075660811 @default.
• W2129202918 hasAuthorship W2129202918A5076348323 @default.
• W2129202918 hasAuthorship W2129202918A5082418715 @default.
• W2129202918 hasAuthorship W2129202918A5084717735 @default.
• W2129202918 hasAuthorship W2129202918A5089729434 @default.
• W2129202918 hasAuthorship W2129202918A5090171528 @default.
• W2129202918 hasBestOaLocation W21292029181 @default.

• next